Paweł Kozyra, Maciej Masłyk

Chemistry - A European Journal

DOI: 10.1002/chem.71733

Abstract

Organic chemistry sits at a pivotal moment. Two decades after combinatorial chemistry promised to industrialize molecule making, the field has converged on a far more interesting reality: medicinal chemists now operate at the intersection of new catalytic paradigms, biological‐scale automation, machine learning, and an expanding set of therapeutic modalities that look very little like the flat aromatic scaffolds of the 1990s. This Perspective surveys the dominant trends shaping contemporary organic synthesis in the context of drug discovery—late‐stage C─H functionalization, photoredox and electrochemical catalysis, biocatalysis, continuous flow manufacturing, AI‐guided retrosynthesis, DNA‐encoded libraries (DELs), and proximity‐based modalities such as PROTACs and molecular glues—and discusses how their convergence is redefining how molecules are designed, made, and validated. The future of the discipline lies not in any single breakthrough, but in the controlled integration of these threads into closed‐loop, data‐rich, and increasingly autonomous discovery pipelines. We also identify open challenges: predictability of complex sp 3 ‐rich scaffolds, scalability of new modalities, environmental footprint, and the need for chemistry education and infrastructure to keep pace with computational advances.